COMPARE · Reviewed July 30, 2026
ANIP vs BHC
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 84.2, BHC scored 70.1 — ANIP leads.
Compare another set
ANIP
ANI Pharmaceuticals, Inc.
84.2
$80.43 · $1.8B
fundamentals as of
Score gap
14.1
ANIP leads
BHC
Bausch Health Companies Inc.
70.1
$6.03 · $2.3B
fundamentals as of
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
BHC
64
Qualityreturns · margins · balance sheet
63
100
Growthrevenue & earnings expansion
64
93
Valuevaluation vs sector peers
86
ANIP is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
ANIP
BHC
$191mC
FCF
$1.4bC+
+37.0%A
Rev
+10.1%B
1.12C
D/E
—
20.6xB+
P/E
—
0.47A
PEG
0.01A
—
P/S
0.2xA
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
BHC
49% below
Price vs fair valuelower is cheaper
87% below
~-7%/yr
Growth the price implies10-yr FCF · lower = less priced in
decline
+71%
1-yr DCF upside
+767%
+97%
5-yr DCF upside
+684%
+142%
10-yr DCF upside
+583%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ANIP
No notable signals flagged.
BHC
Why this score
- Short track record
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.8b. 19% off the 52-week high of $99.50. Revenue growing +37% — in hypergrowth territory. PEG 0.47 — paying under fair value for the growth rate. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $110.00 (implying +37% upside).
Moat
ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
BHCBausch Health Companies Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $2.3b. Down 31% from 52-week high of $8.69 — deep drawdown territory. Revenue growing +10%, comfortably above the S&P median. PEG 0.01 — paying under fair value for the growth rate. 5 sell-side analysts rate this a Hold with a mean 1-yr target of $7.30 (implying +21% upside).
Moat
ROE 62% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -10.1%) — path to GAAP profitability is the core thesis risk. Down 31% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.